Expression and Role of the JAK/STAT Pathway in Sarcoidosis Granuloma Cells (JAK-SARC)

Assistance Publique - Hôpitaux de Paris

Status: Enrolling

Conditions: Sarcoidosis; JAK-STAT Pathway Deregulation

Treatments: Other: Blood sample

Study type: Observational

Funder types: Other

Identifiers

NCT04751279

APHP201205

2020-A02330-39 (Other Identifier)

Details and patient eligibility

About

Recent studies suggest that the JAK/STAT signaling pathway constitutes a new step in the clinical and therapeutic progress of sarcoidosis. Further investigations are necessary to identify the most suitable patients to receive treatment targeting this pathway, in particular in cases of severe sarcoidosis refractory to the various therapeutic lines.

Full description

The investigators hypothesize that the JAK/STAT signaling pathway constitutes a new step in the clinical and therapeutic progress of sarcoidosis, in particular in cases of severe sarcoidosis refractory to the various therapeutic lines. The main objective of this proposal is to evaluate the presence and stage of activation of the JAK/STAT pathway in PBMCs from inactive and active sarcoidosis patients. The second objective will be to determine the role of the JAK/STAT pathway in the formation and maintenance of granulomas and their association with the severity of sarcoidosis and fibrogenesis.

Enrollment: 80 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with a diagnosis of mediastinopulmonary sarcoidosis made according to ATS / ERS / WASOG criteria
• Or patient suspected of having mediastino-pulmonary sarcoidosis, without any other probable causal factor identified on the usual standard examination at the time of the sample with the need for diagnostic confirmation at the end of the study according to the criteria of the ATS / ERS / WASOG
• Sarcoidosis with stage 1 to 4 pulmonary involvement
• Patients who had a chest CT scan in the 6 months preceding the sample. Examination carried out as part of routine care

Exclusion criteria

• Pregnancy.
• Opposition expressed to participation in the study.
• Patients on State Medical Aid.

Trial design

80 participants in 4 patient groups

Patients with pulmonary sarcoidosis without signs of chest activity and recent diagnosis (<5 years)

Description:

Patients with pulmonary sarcoidosis without signs of chest activity (Benamore score \<2) and recent diagnosis (\<5 years)

Treatment:

Other: Blood sample

Patients with pulmonary sarcoidosis with signs of chest activity and recent diagnosis (<5 years

Description:

Patients with pulmonary sarcoidosis with signs of chest activity (Benamore score ≥2) and recent diagnosis (\<5 years)

Treatment:

Other: Blood sample

Patients with pulmonary sarcoidosis without signs of activity , persistent form (>5 years)

Description:

Patients with pulmonary sarcoidosis without signs of activity (Benamore score \<2), persistent form (\>5 years)

Treatment:

Other: Blood sample

Patients with pulmonary sarcoidosis with signs of chest activity , persistent form (>5 years)

Description:

Patients with pulmonary sarcoidosis with signs of chest activity (Benamore score ≥2), persistent form (\>5 years)

Treatment:

Other: Blood sample